• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Giuseppe Saglio Compares Efficacy, Safety of Nilotinib With Imatinib for CML Patients

Video

Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib's side effects are too much for patients.

Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib’s side effects are too much for patients, according to a study from Novartis presented at the 56th Annual Meeting of the American Society of Hematology.

Giuseppe Saglio, MD, one of the co-authors on the study and a professor of internal medicine at the University of Turin in Italy, explained that while just 10% of patients who stopped imatinib did so because of side effects, 20% of patients on nilotinib stopped treatment because of side effects.

“So I think, probably, we have to reconsider all this data to suggest which is the best appropriate treatment and particular dosage of the drug as first-line therapy,” Dr Saglio said.

Related Videos
Frederick L Locke, MD, Moffitt
Pierluigi Porcu, MD
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Andrew Kuykendall, MD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Andrew Kuykendall, MD, Moffitt Cancer Center
Ajai Chari, MD
Cathy Eng, MD, FACP, FASCO
Andrew Kuykendall, MD, Moffitt Cancer Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.